FGFR1 amplification and/or mRNA overexpression is present in around 15% of ER+ breast cancer (Fig. 2) and has been associated with early relapse following adjuvant tamoxifen and with poor survival in ER+ breast cancer14. Here, FGFR1 is linked to breast cancer.